2026 Q3 - tulosraportti
4 päivää sitten
‧34 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 2.3. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·4 t sitten · MuokattuXeris is without a doubt one of the fastest-growing pharmaceutical companies in the world and combines exceptionally high profit margins with a potential on par with the very large pharmaceutical corporations (a potential of several billion dollars, even without counting potential sales outside the US). To put it into perspective: Corcept had revenues of 361 million USD in 2021 and 761 million USD in 2025. This corresponds to a growth of exactly 400 million USD. Impressive! The company's valuation peaked at 11-12 billion USD in 2025, driven by growth and future potential. Xeris expects a revenue of around 400 million USD in 2026 and estimates reaching 1 billion USD in 2030. This corresponds to a potential revenue growth of 600 million USD – a completely phenomenal development, where XP-8121 will contribute along with Recorlev and the company's other proprietary products. Conclusion: If this growth curve becomes a reality, a maximum valuation of 15-20 billion USD in 2030 is certainly not unthinkable. This will correspond to a share price of approximately 82-109 USD per share (before potential share buybacks). Revenue heading towards 1 billion, already without the block buster XP-8121
·22 t sittenAnyone who has any thoughts on the rumors of an acquisition of xers?It was Lundbeck that had investigated the possibility. They cannot afford it, they might be able to push it up to 16-18$ usd per share but why sell it when the share price before 2030 easily is 40-60 and even more a few years into 2030.. Xers is quickly on its way to becoming expensive to acquire.
·2 päivää sittenI bought this about 1.5 years ago at 8.3 USD. 1 year ago I recommended this stock to a friend of mine, a full 5 hours before a pathetic quarterly report that sent the stock down 25%. Since then I have received well-deserved scolding from him, and I realize that it wasn't one of my proudest moments. Lately (the last 2 days) I've been hearing a lot of nice things from my buddy again, which is definitely an extra return on the fantastic 41% we've climbed this week. Looking forward immensely to seeing the development of XERS and "steering" the company together with all of you going forward 😊📈
·3 päivää sittenI bought this a year ago, 5 hours before the quarterly report came out, and the company dropped 25% right away. I didn't believe my own eyes when I first saw it. Despite that, I held. At worst, I was down -40%. Today I am at +25%. This has been a completely emotional investment and I recognize that it was not financially wise. Still, very fun to see that the numbers are finally green after a heavy and long year :)Bought it 5-6 years ago at 3.95 when it dropped to 1.3-1$ I bought as much as I could because it smelled like it will make a trdm, amd and where they start generating money.. It took longer than I thought but it just started it's easily 30-60 in 2030 or more in 2033- ·3 päivää sittenepic regnkab.. 1b revenue in 2030.. 44% increase compared to last year, 16% increase compared to last quarter.. and the good stuff hasn't even arrived yet ;)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
4 päivää sitten
‧34 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sitten · MuokattuXeris is without a doubt one of the fastest-growing pharmaceutical companies in the world and combines exceptionally high profit margins with a potential on par with the very large pharmaceutical corporations (a potential of several billion dollars, even without counting potential sales outside the US). To put it into perspective: Corcept had revenues of 361 million USD in 2021 and 761 million USD in 2025. This corresponds to a growth of exactly 400 million USD. Impressive! The company's valuation peaked at 11-12 billion USD in 2025, driven by growth and future potential. Xeris expects a revenue of around 400 million USD in 2026 and estimates reaching 1 billion USD in 2030. This corresponds to a potential revenue growth of 600 million USD – a completely phenomenal development, where XP-8121 will contribute along with Recorlev and the company's other proprietary products. Conclusion: If this growth curve becomes a reality, a maximum valuation of 15-20 billion USD in 2030 is certainly not unthinkable. This will correspond to a share price of approximately 82-109 USD per share (before potential share buybacks). Revenue heading towards 1 billion, already without the block buster XP-8121
- ·22 t sittenAnyone who has any thoughts on the rumors of an acquisition of xers?It was Lundbeck that had investigated the possibility. They cannot afford it, they might be able to push it up to 16-18$ usd per share but why sell it when the share price before 2030 easily is 40-60 and even more a few years into 2030.. Xers is quickly on its way to becoming expensive to acquire.
- ·2 päivää sittenI bought this about 1.5 years ago at 8.3 USD. 1 year ago I recommended this stock to a friend of mine, a full 5 hours before a pathetic quarterly report that sent the stock down 25%. Since then I have received well-deserved scolding from him, and I realize that it wasn't one of my proudest moments. Lately (the last 2 days) I've been hearing a lot of nice things from my buddy again, which is definitely an extra return on the fantastic 41% we've climbed this week. Looking forward immensely to seeing the development of XERS and "steering" the company together with all of you going forward 😊📈
- ·3 päivää sittenI bought this a year ago, 5 hours before the quarterly report came out, and the company dropped 25% right away. I didn't believe my own eyes when I first saw it. Despite that, I held. At worst, I was down -40%. Today I am at +25%. This has been a completely emotional investment and I recognize that it was not financially wise. Still, very fun to see that the numbers are finally green after a heavy and long year :)Bought it 5-6 years ago at 3.95 when it dropped to 1.3-1$ I bought as much as I could because it smelled like it will make a trdm, amd and where they start generating money.. It took longer than I thought but it just started it's easily 30-60 in 2030 or more in 2033
- ·3 päivää sittenepic regnkab.. 1b revenue in 2030.. 44% increase compared to last year, 16% increase compared to last quarter.. and the good stuff hasn't even arrived yet ;)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 2.3. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
4 päivää sitten
‧34 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 2.3. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·4 t sitten · MuokattuXeris is without a doubt one of the fastest-growing pharmaceutical companies in the world and combines exceptionally high profit margins with a potential on par with the very large pharmaceutical corporations (a potential of several billion dollars, even without counting potential sales outside the US). To put it into perspective: Corcept had revenues of 361 million USD in 2021 and 761 million USD in 2025. This corresponds to a growth of exactly 400 million USD. Impressive! The company's valuation peaked at 11-12 billion USD in 2025, driven by growth and future potential. Xeris expects a revenue of around 400 million USD in 2026 and estimates reaching 1 billion USD in 2030. This corresponds to a potential revenue growth of 600 million USD – a completely phenomenal development, where XP-8121 will contribute along with Recorlev and the company's other proprietary products. Conclusion: If this growth curve becomes a reality, a maximum valuation of 15-20 billion USD in 2030 is certainly not unthinkable. This will correspond to a share price of approximately 82-109 USD per share (before potential share buybacks). Revenue heading towards 1 billion, already without the block buster XP-8121
- ·22 t sittenAnyone who has any thoughts on the rumors of an acquisition of xers?It was Lundbeck that had investigated the possibility. They cannot afford it, they might be able to push it up to 16-18$ usd per share but why sell it when the share price before 2030 easily is 40-60 and even more a few years into 2030.. Xers is quickly on its way to becoming expensive to acquire.
- ·2 päivää sittenI bought this about 1.5 years ago at 8.3 USD. 1 year ago I recommended this stock to a friend of mine, a full 5 hours before a pathetic quarterly report that sent the stock down 25%. Since then I have received well-deserved scolding from him, and I realize that it wasn't one of my proudest moments. Lately (the last 2 days) I've been hearing a lot of nice things from my buddy again, which is definitely an extra return on the fantastic 41% we've climbed this week. Looking forward immensely to seeing the development of XERS and "steering" the company together with all of you going forward 😊📈
- ·3 päivää sittenI bought this a year ago, 5 hours before the quarterly report came out, and the company dropped 25% right away. I didn't believe my own eyes when I first saw it. Despite that, I held. At worst, I was down -40%. Today I am at +25%. This has been a completely emotional investment and I recognize that it was not financially wise. Still, very fun to see that the numbers are finally green after a heavy and long year :)Bought it 5-6 years ago at 3.95 when it dropped to 1.3-1$ I bought as much as I could because it smelled like it will make a trdm, amd and where they start generating money.. It took longer than I thought but it just started it's easily 30-60 in 2030 or more in 2033
- ·3 päivää sittenepic regnkab.. 1b revenue in 2030.. 44% increase compared to last year, 16% increase compared to last quarter.. and the good stuff hasn't even arrived yet ;)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt